

**Brilliant Violet 510™ anti-mouse Ly-6G/Ly-6C (Gr-1)**

**Catalog # / Size:** 1142190 / 500 µl  
1142185 / 125 µl  
1142285 / 50 µg

**Clone:** RB6-8C5

**Isotype:** Rat IgG2b, κ


**Immunogen:** Raised against granulocytes of mouse origin

**Reactivity:** Mouse

**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 510™ and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

**Concentration:** Lot-specific



C57BL/6 mouse bone marrow cells were stained with Ly-6G/Ly-6C (clone RB6-8C5) Brilliant Violet 510™ (filled histogram) or rat IgG2b, κ Brilliant Violet 510™ isotype control (open histogram). Data shown was gated on myeloid cell population

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application Notes:** Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C<sup>19</sup>. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A8<sup>19</sup>. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.4<sup>20</sup>.

The RB6-8C5 antibody has been used to identify peripheral blood neutrophils and deplete granulocytes *in vivo*. Additional reported applications (for relevant formats of this clone) include: *in vitro* complement-mediated cytotoxicity<sup>2</sup>, *in vivo*

depletion<sup>3-5,9</sup>, immunoprecipitation<sup>1</sup>, immunohistochemical staining<sup>6</sup> (including paraffin-embedded sections<sup>9,16</sup>, acetone-fixed frozen sections<sup>11</sup> and zinc-fixed sections<sup>15</sup>), and Western blotting<sup>7</sup>. RB6-8C5 is not suitable for depletion of hepatic myeloid derived suppressor cells (MDSCs)<sup>20</sup>.

**Special Note:** The LEAF™ purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays (Cat. No. 108414). For *in vivo* studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 108436) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/microg).

- Application** 1. Fleming TJ, *et al.* 1993. *J. Immunol.* 151:2399. (IP)
- References:** 2. Brummer E, *et al.* 1984. *J. Leukocyte Biol.* 36:505. (CMCD)
3. Stoppacciaro A, *et al.* 1993. *J. Exp. Med.* 178:151. (Deplete)
4. Tumpey TM, *et al.* 1996. *J. Virol.* 70:898. (Deplete)
5. Czuprynski CJ, *et al.* 1994. *J. Immunol.* 152:1836. (Deplete)
6. Nitta H, *et al.* 1997. *Cell Vision* 4:73. (IHC)
7. Jutila MA, *et al.* 1988. *Eur. J. Immunol.* 18:1819. (WB)
8. Engwerda CR, *et al.* 2004. *Am. J. Pathol.* 165:2123.
9. Brown CR, *et al.* 2004. *Infect. Immun.* 72:4956. (Deplete, IHC)
10. Andoniou CE, *et al.* 2005. *Nature Immunology* 6:1011. (FC) [PubMed](#)
11. Li M, *et al.* 2006. *P. Natl. Acad. Sci USA* 103:11736. (IHC)
12. Dzhagalov I, *et al.* 2007. *Blood* 109:1620. (FC) [PubMed](#)
13. Fazilleau N, *et al.* 2007. *Nature Immunol.* 8:753. (FC) [PubMed](#)
14. Heuser M, *et al.* 2007. *Blood* 110:1639. (FC) [PubMed](#)
15. Wang T, *et al.* 2007. *Infect. Immun.* 75:1144. (IHC)
16. Bosio CM, *et al.* 2007. *J. Immunol.* 178:4538. (IHC)
17. Boehme SA, *et al.* 2009. *Int. Immunol.* 21:81. (IHC)
18. Piao Y, *et al.* 2012. *Neuro Oncol.* 14:1379. [PubMed](#)
19. Ribechini E, *et al.* 2009. *Eur. J. Immunol.* 39:3538.
20. Ma C, *et al.* 2012. *J. Leukoc. Biol.* 92:1199.
- 

**Description:** Gr-1 is a 21-25 kD protein also known as Ly-6G/Ly-6C. This myeloid differentiation antigen is a glycosylphosphatidylinositol (GPI)-linked protein expressed on granulocytes and macrophages. In bone marrow, the expression levels of Gr-1 directly correlate with granulocyte differentiation and maturation; Gr-1 is also transiently expressed on bone marrow cells in the monocyte lineage. Immature Myeloid Gr-1+ cells play a role in the development of antitumor immunity.

- Antigen** 1. Fleming TJ, *et al.* 1993. *J. Immunol.* 151:2399.
- References:** 2. Jutila MA, *et al.* 1988. *Eur. J. Immunol.* 18:1819.
3. Goni O, *et al.* 2002. *Int. Immunol.* 14:1125.